• Skip to main content
logo-4800
  • Home
  • Team
  • Portfolio
  • News
  • Contact Us
×
  • Home
  • Team
  • Portfolio
  • News
  • Contact Us

NEWS AND UPDATES

Biosana enters exclusive global licensing agreement with Alvotech for co-development of a Proposed Biosimilar (AVT23) to Xolair® (Omalizumab)

2nd February, 2022

Leiden, February 2, 2022 –  BiosanaPharma, a Gold Nest Capital portfolio company, has entered into a global licensing agreement with Alvotech to co-develop BP001, a biosimilar of Xolair (omalizumab). Under this agreement, BiosanaPharma and Alvotech…

Read More

Allecra Therapeutics and Advanz Pharma Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe

13th January, 2022

SAINT-LOUIS, France and WEIL AM RHEIN, Germany and LONDON, UK, January 13, 2022 –  ADVANZ PHARMA Corp. Limited (“ADVANZ PHARMA”), a specialty pharmaceutical company with a strategic focus on hospital medicines in Europe, and Allecra…

Read More

BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies

10th January, 2022

MAINZ, Germany and CAMBRIDGE, UK, January 10, 2022 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Crescendo Biologics Ltd (“Crescendo”), a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, today announced that they have entered…

Read More

Insights on the Biochips Global Market to 2026

20th December, 2021

Dublin, December 20, 2021 – The global biochips market exhibited strong growth during 2015-2020. Looking forward, the market is expected to grow at a CAGR of around 15% during 2021-2026. Keeping in mind the uncertainties…

Read More

Topas Therapeutics Extends Series B, Raising Total of €40 Million (~$ 48 Million) in this Round

29th July, 2021

HAMBURG, GERMANY / July 29, 2021 – Topas Therapeutics (Topas), a private biotechnology company developing immune tolerance-inducing drugs to treat and potentially cure a variety of autoimmune diseases, today announced that the Company has successfully…

Read More

MIMETAS wins Deshima award for Dutch-Japanese business relations

7th July, 2021

Leiden & Tokyo, June 7, 2021 – MIMETAS has been awarded the “Deshima Business Award” in the category “newly established” by the Netherlands Chamber of Commerce in Japan (NCCJ), and the Embassy of the Kingdom…

Read More

MIMETAS and Roche Enter into a Collaboration to Develop Human Disease Models for Drug Development

6th July, 2021

Leiden, July 6, 2021 – MIMETAS, a leader in organ-on-chip-based disease models and technology, and Roche, a world-leading pharmaceutical company, announced today that they have entered into a collaboration to develop human disease models to…

Read More

Nature Communication publishes application of switchSENSE technology in multivalent antibody development

18th June, 2021

Leiden, July 18, 2021 – Today, Andreas Plückthun’s group at the University of Zurich publishes on Nature Communication with the help of switchSENSE technology. The paper shows that an engineered anti-Her2 tetravalent antibody construct that…

Read More

UK eases the way to market for biosimilars

6th May, 2021

Today, UK’s Medicines & Healthcare products Regulatory Agency (MHRA) published the final guidance on the licensing of biosimilar products, lowering the barrier for biosimilar drug to enter the market. Today’s final version follows draft guidelines…

Read More

Conformation analysis realized by switchSENSE published in Proceedings of National Academy of Science

30th March, 2021

La Jolla, LA, March 30, 2021 – Litao Sun, et al, at Scripps Research used the switchSENSE® technology in their paper to analyze the different conformations of the wild-type and mutant versions of the alanyl-tRNA…

Read More
  • 1
  • 2
  • Next »

© Copyright 2022 Gold Nest Capital. All Rights Reserved.

  • WordPress Web Design